FREMONT, Calif., Sept. 2, 2019 /PRNewswire/ -- Ardelyx, Inc.
(NASDAQ: ARDX), a specialized biopharmaceutical company focused on
developing first-in-class medicines to improve treatment for people
with cardiorenal diseases, announced that it will hold a conference
call tomorrow, September 3, at
8:30 am Eastern Time to review the
results from the pivotal Phase 3 AMPLIFY study of tenapanor in
combination with phosphate binders in patients with chronic kidney
disease on dialysis whose hyperphosphatemia was not controlled with
binders. Tenapanor is Ardelyx's investigational, first-in-class,
small molecule, non-binder, phosphate absorption inhibitor.
To participate in the conference call, please dial (855)
296-9612 (domestic) or (920) 663-6277 (international) and refer to
conference ID 9789472. Live audio of the conference call will be
simultaneously webcast and will be available under the Investors
section of the company's website at www.ardelyx.com. The
webcast will be archived and available for replay for 60 days
following the call.
About Ardelyx, Inc.
Ardelyx is focused on enhancing
the lives of people with cardiorenal diseases by developing
first-in-class medicines that matter. Ardelyx's cardiorenal
pipeline includes the Phase 3 development of tenapanor for the
treatment of hyperphosphatemia in people with CKD on dialysis, and
RDX013, a potassium secretagogue program for the potential
treatment of high potassium, or hyperkalemia, a problem among
certain patients with kidney and/or heart disease. In addition,
Ardelyx has completed Phase 3 development of tenapanor for the
treatment of irritable bowel syndrome with constipation (IBS-C) and
submitted a new drug application, or NDA, to the U.S. Food and Drug
Administration, or FDA, for the treatment of patients with IBS-C
which has been granted a target action date under the Prescription
Drug User Fee Act (PDUFA) of September 12,
2019. To efficiently bring its treatments to market, Ardelyx
is pursuing strategic collaborations for tenapanor for IBS-C and
hyperphosphatemia in certain territories. Ardelyx has established
agreements with Kyowa Kirin Co., Ltd. in Japan, Fosun Pharma in China and Knight Therapeutics in Canada. For more information, please visit
http://www.ardelyx.com and connect with us on Twitter @Ardelyx.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ardelyx-to-host-conference-call-on-september-3-to-review-results-from-the-pivotal-phase-3-amplify-study-300910304.html
SOURCE Ardelyx